|Table of Contents|
Immunomodulatory treatments for relapsing–remitting multiple sclerosis
Published in : HAMDAN MEDICAL JOURNAL ; Vol 10, No 4 (2017)
DOI : 10.7707/hmj.806
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that encompasses both neuroinflammatory and prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and, until recently, licensed drugs could not satisfactorily halt this process. However, in recent years, MS treatment has entered a phase of rapid progress. Several new drugs with significantly improved efficacy have entered the therapeutic field, and several others are currently undergoing phase III clinical trials. In this review, the efficacy data and safety and tolerability issues of currently licensed drugs for relapsing–remitting MS will be summarized, including a short update on new drugs currently undergoing late-stage clinical trials.